AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 5483323
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate administered with doxycycline
Trial: 5483323
Drug: Small doses
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small doses of iron taken simultaneously with tetracycline
Trial: 25848072
Drug: Shock-wave (SW)
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock-wave (SW) therapy
Trial: 19487995
Drug: Deep breathing
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep breathing exercises along with usual treatment for pain
Trial: 19487995
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment for pain (Control)
Trial: 22748821
Drug: Glimepiride (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1-4 mg)
Trial: 8086025
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.5% bupivacaine
Trial: 3353525
Drug: thoracic EA
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thoracic EA with bupivacaine (0.5%) in combination with a light general anesthesia
Trial: 21614414
Drug: cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilostazol 100 mg
Trial: 12718508
Drug: Ivermectin capsules
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin capsules
Trial: 9928754
Drug: Verapamil SR/trandolapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil SR/trandolapril 120/0.5 mg o.d. (dose step 1)
Trial: 9928754
Drug: Verapamil SR/trandolapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil SR/trandolapril 180/2 mg o.d. (dose step 3)
Trial: 8601264
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs, sunscreens, topical and intra-lesional corticosteroids, antimalarials
Trial: 8601264
Drug: High-dose corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose corticosteroids or immunosuppressants
Trial: 8601264
Drug: Antihypertensives, cholesterol-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensives, cholesterol-lowering drugs, hypoglycemic agents
Trial: 7471064
Drug: Pseudoisocytidine (psi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoisocytidine (psi ICyd) administered via daily i.v. injection for 5 consecutive days
Trial: 21083737
Drug: Ricinus communis
RxNorm normalized name: Ricinus communis oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ricinus communis solution (RC)
Trial: 8641247
Drug: Blackcurrant-strawberry nectar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blackcurrant-strawberry nectar (200 ml, twice daily for 4-5 weeks, vitamin C content approximately 70 mg/100 g)
Trial: 1727913
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 every 21 days IV)
Trial: 1727913
Drug: ICRF‐187 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICRF‐187 1,000 mg/m2 IV
Trial: 15673327
Drug: Cinacalcet (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (30 to 180 mg/day)
Trial: 3280097
Drug: Intravenous urography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous urography
Trial: 7193307
Drug: Levodopa administered
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa administered rectally
Trial: 29145211
Drug: S-1 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 therapy
Trial: 22143488
Drug: Problem-Solving Treatment
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-Solving Treatment (adapted for prevention of depression)
Trial: 17400086
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (EPO) 600 IU/kg once weekly for 4 doses
Trial: 15877947
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment based on traditional Chinese medical differentiation
Trial: 16959151
Drug: General treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General treatment
Trial: 8633913
Drug: Protein-sparing therapy
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-sparing therapy group
Trial: 1769603
Drug: Hydralazine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine 40 mg per os every 6 hrs, plus sublingual nifedipine (used if diastolic pressure of 110 mmHg or more)
Trial: 24661333
Drug: Degarelix 80
RxNorm normalized name: degarelix 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix 80 mg
Trial: 24661333
Drug: Degarelix 160
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix 160 mg
Trial: 24661333
Drug: Degarelix 240/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix 240/80 mg (crossover from leuprolide)
Trial: 24661333
Drug: Degarelix 240/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix 240/160 mg (crossover from leuprolide)
Trial: 22161728
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg annually for 6 years (Z6, n = 616)
Trial: 22161728
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg annually for 6 years (Z6)
Trial: 12198987
Drug: 15% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% carbamide peroxide and 0.11% fluoride ion gel
Trial: 9755033
Drug: 50 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 Hz magnetic field exposure (20 microT, 200 mG)
Trial: 350251
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium valproate (800 mg)
Trial: 350251
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium valproate (800 mg)
Trial: 31619057
Drug: Intravenous busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous busulfan (BU) pre-transplant
Trial: 26732142
Drug: Nebulized hypertonic
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized hypertonic saline (3 mL, 4 times/day)
Trial: 26732142
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline, 3 mL, 4 times/day)
Trial: 12390102
Drug: R40C800 (Rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R40C800 (Rabeprazole 20 mg + Amoxicillin 750 mg + Clarithromycin 400 mg, twice daily)
Trial: 12390102
Drug: LAC (Lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC (Lansoprazole + Amoxicillin + Clarithromycin)
Trial: 1976543
Drug: Oral PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral PGE2 tablets
Trial: 31336497
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g soy nut diet for 8 weeks
Trial: 28801554
Drug: Delayed fractional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed fractional dose regimen of the RTS,S malaria vaccine (0-1-7 month schedule, third dose at 20% of full dose)
Trial: 15081178
Drug: Community consultation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community consultation (CC) and public disclosure (PD) activities conducted by investigators
Trial: 11864862
Drug: Dietary magnesium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary magnesium intake less than 160 mg/d (less than half of the recommended dietary allowance)
Trial: 10753423
Drug: Arlevert therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arlevert therapy
Trial: 31588657
Drug: Rongliflozin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rongliflozin (20 mg with food in healthy participants)
Trial: 31588657
Drug: Rongliflozin (10-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rongliflozin (10-50 mg once daily for 12 days in T2DM)
Trial: 31588657
Drug: Rongliflozin (10-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rongliflozin (10-200 mg single ascending dose in healthy participants)
Trial: 17906188
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of massage therapy
Trial: 17906188
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days without massage therapy
Trial: 16142136
Drug: Prépidil (prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prépidil (prostaglandin gel)
Trial: 28658164
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride 0.06 mg/kg (group A)
Trial: 28658164
Drug: Oxycodone hydrochloride
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone hydrochloride 0.08 mg/kg (group B)
Trial: 19629461
Drug: Standard FK506-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard FK506-based immunosuppressant regimen only (Control)
Trial: 16958739
Drug: Natural mineral
RxNorm normalized name: ZINC OXIDE 8.25 g in 44 mL TOPICAL LOTION [Natural Mineral Formula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural mineral dietary supplement (NMDS), 1 l, swished twice a day
Trial: 16958739
Drug: Placebo (de-ionized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (de-ionized water), 1 l, swished twice a day
Trial: 16958739
Drug: Natural mineral
RxNorm normalized name: ZINC OXIDE 8.25 g in 44 mL TOPICAL LOTION [Natural Mineral Formula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural mineral dietary supplement (NMDS)
Trial: 12864878
Drug: Perindopril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril treatment program
Trial: 12864878
Drug: Historical controls
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical controls (no treatment or inconsistent treatment)
Trial: 10695647
Drug: Interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal psychotherapy (IPT) and pharmacotherapy initiated at the outset of treatment
Trial: 10695647
Drug: Interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal psychotherapy (IPT) alone first, then combination therapy for non-remitters
Trial: 3215161
Drug: Relapse-prevention (RP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse-prevention (RP) treatment
Trial: 29258724
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral radiocontrast (baseline)
Trial: 22421690
Drug: Monthly antibiotic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly antibiotic treatment (ciprofloxacin or azithromycin) for 9 months
Trial: 22421690
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 9 months
Trial: 14519709
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg for weight <40 kg or 500 mg for weight ≥40 kg) administered orally 3 days a week for 168 days
Trial: 14519709
Drug: Placebo (identically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identically packaged tablets)
Trial: 1851785
Drug: Combined potassium‐losing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined potassium‐losing and ‐sparing diuretic (triamterene 50 mg plus hydrochlorothiazide 25 mg)
Trial: 7226124
Drug: CDVFP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDVFP + MER (0.4 mg S.C. every four weeks)
Trial: 7226124
Drug: CD/MF +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD/MF + MER (0.4 mg S.C. every four weeks)
Trial: 25758100
Drug: Type 1
RxNorm normalized name: Type 1 H substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 1 implant placement
Trial: 19697206
Drug: Superficial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial injection of local anaesthetic prior to deep injection into the cervix
Trial: 19697206
Drug: Deep injection
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep injection into the substance of the cervix (Control)
Trial: 18389594
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (Ursosan), 3-month course of treatment
Trial: 7994224
Drug: Treatment consisting
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment consisting of cleaning, depuration and motivation
Trial: 2455442
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of 20 mg of PEP/20 ml of saline for 4 weeks
Trial: 2455442
Drug: Weekly instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly instillation of 20 mg of PEP/20 ml of saline for 8 weeks after TUR
Trial: 18289228
Drug: Balanced salt-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced salt-based high molecular weight HES solution (670/0.75)
Trial: 18289228
Drug: Saline-based low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline-based low molecular weight HES solution (130/0.4)
Trial: 1550052
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg manganese daily
Trial: 22584544
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl wafer (100 μg)
Trial: 22584544
Drug: IV fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl (100 μg)
Trial: 20425759
Drug: FVB capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FVB capsules
Trial: 1952134
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (10 mg)
Trial: 8951195
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (2 g)
Trial: 7614898
Drug: Zidovudine syrup
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine syrup (2 mg/kg administered 6-hourly for 6 weeks)
Trial: 1975321
Drug: Alteplase (tPA,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (tPA, 100 mg infused intravenously over 3 h)
Trial: 1975321
Drug: Heparin (12,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (12,500 U subcutaneously twice daily until discharge, starting 12 h after beginning the tPA or SK infusion)
Trial: 1975321
Drug: SK and
RxNorm normalized name: Ispaghula husk and mebeverine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK and heparin
Trial: 4913961
Drug: Oral ergotamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ergotamine tartrate
Trial: 28668386
Drug: No transplantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No transplantation group (full course of rituximab-dose-dense chemotherapy)
Trial: 21719078
Drug: Anti-IL-13 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL-13 (6 mg/kg intravenously)
Trial: 16352815
Drug: Deferoxamine (43
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferoxamine (43 mg/kg for 5.7 d/wk)
Trial: 15285851
Drug: lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole (30 mg per day for 4 days)
Trial: 11919104
Drug: Nebulised levo-adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised levo-adrenaline (3 mg in 3 ml)
Trial: 8864962
Drug: Sitostanol ester
RxNorm normalized name: disodium ascorbyl sitostanol phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitostanol ester margarine (3 g/day)
Trial: 7053889
Drug: Sequential studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential studies
Trial: 26582805
Drug: Continuous intraperitoneal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intraperitoneal insulin infusion (CIPII)
Trial: 794978
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 8 weeks
Trial: 8398292
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (MMC, BCG-Tice, BCG-RIVM)
Trial: 3297218
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose prednisone (0.5 mg/kg body weight)
Trial: 3297218
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose prednisone (2.0 mg/kg body weight)
Trial: 31327047
Drug: Low FODMAP
RxNorm normalized name: ProNourish Low FODMAP Enteral Suspension (French Vanilla)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low FODMAP diet plus Bacillus coagulans supplementation (109 B. coagulans spores and 400 mg inulin)
Trial: 22843218
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline injection (painful)
Trial: 25879794
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection (control)
Trial: 15056094
Drug: Nurse-administered propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered propofol sedation (NAPS)
Trial: 16105183
Drug: Glycine (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine (multiple intravenous doses)
Trial: 6504708
Drug: Indacrinone enantiomer
RxNorm normalized name: Inamrinone
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indacrinone enantiomer combinations (10 mg (−) enantiomer + 40, 90, and 140 mg (+) enantiomer)
Trial: 730416
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg)
Trial: 22331983
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins (5-methyltetrahydrofolate 0.56 mg, vitamin B6 3 mg, vitamin B12 0.02 mg)
Trial: 22331983
Drug: ω-3 fatty
RxNorm normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 fatty acids (eicosapentaenoic and docosahexaenoic acid 600 mg)
Trial: 12213517
Drug: D-amphetamine (AMPH;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (AMPH; 15 mg oral)
Trial: 7745465
Drug: Heparin (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (continuous intravenous infusion)
Trial: 7745465
Drug: Monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring of anticoagulants
Trial: 28647169
Drug: Same-day preschool
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day preschool vaccinations (number of injections between ages four and six years)
Trial: 28647169
Drug: Parent vaccine
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent vaccine anxiety (VAS>50)
Trial: 25405571
Drug: Low-dose estradiol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose estradiol (E2) 0.5 mg/day
Trial: 15679621
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR 75 mg/day
Trial: 23644225
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with UPPP
Trial: 22013952
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of 20% albumin
Trial: 22013952
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of 4% gelatin
Trial: 15228864
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 0.75 ml/kg along with 0.1% midazolam 50mg/kg (group B)
Trial: 15228864
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 0.75 ml/kg (group A)
Trial: 11953729
Drug: Indwelling catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indwelling catheter injections